- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1977
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: Afatinib in advanced NSCLC: a profile of its use ; volume:34 ; number:4 ; day:16 ; month:2 ; year:2018 ; pages:196 ; date:4.2018
Drugs & therapy perspectives ; 34, Heft 4 (16.2.2018), 196, 4.2018
- Urheber
-
Deeks, Emma D.
- Beteiligte Personen und Organisationen
-
Keating, Gillian M.
SpringerLink (Online service)
- DOI
-
10.1007/s40267-018-0490-6
- URN
-
urn:nbn:de:1111-2018052022047
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Deeks, Emma D.
- Keating, Gillian M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Afatinib in advanced NSCLC: a profile of its use
Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
Afatinib (NSCLC mit Plattenepithelhistologie) : Nutzenbewertung gemäß § 35a SGB V
Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study
Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
Stimulation of Eryptosis by Afatinib
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
Afatinib in advanced NSCLC: a profile of its use
Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
Afatinib (NSCLC mit Plattenepithelhistologie) : Nutzenbewertung gemäß § 35a SGB V
Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study
Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
Stimulation of Eryptosis by Afatinib
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
Afatinib in advanced NSCLC: a profile of its use
Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
Afatinib (NSCLC mit Plattenepithelhistologie) : Nutzenbewertung gemäß § 35a SGB V
Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study
Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
Stimulation of Eryptosis by Afatinib